Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.
José M Rodriguez-ValadezMalak TahsinUmesh MasharaniMeyeon ParkM G Myriam HuninkJoseph YeboahLihua LiEllerie WeberAsem BerkalievaLuuk AvezaatWendy B MaxKirsten E FleischmannBart S FerketPublished in: Journal of the American Heart Association (2024)
We confirmed increased efficacy findings for major adverse cardiovascular events with reduction in glycated hemoglobin for GLP1-RAs. Further research is needed on the potential loss of cardiovascular benefits with increased weight loss and hematocrit for SGLT2i.
Keyphrases
- cardiovascular events
- weight loss
- cardiovascular disease
- coronary artery disease
- type diabetes
- bariatric surgery
- glycemic control
- human health
- roux en y gastric bypass
- emergency department
- risk assessment
- adipose tissue
- climate change
- body mass index
- adverse drug
- weight gain
- insulin resistance
- drug induced
- electronic health record